Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from JNJ

Mid-Afternoon Market Update: Nasdaq Surges 200 Points; Dentsply Sirona Shares Plunge

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Tuesday.

Benzinga

Mid-Day Market Update: Crude Oil Down Over 5%; Checkmate Pharmaceuticals Shares Spike Higher

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Tuesday.

Benzinga

BeiGene Shares Updated Data From Tislelizumab Combo Trial In Head & Neck Cancer

BeiGene Ltd (NASDAQ:BGNE) shared updated data analyses from the Phase 3 RATIONALE-309 trial of tislelizumab combined with chemotherapy versus chemotherapy plus placebo in first-line recurrent or metastatic nasopharyngeal cancer. Updated efficacy analyses showed that, at a median follow-up of 15.5 months, tislelizumab/chemotherapy combo demonstrated a clinically significant progression-free survival (PFS) benefit over chemotherapy…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Mid-Morning Market Update: Markets Open Higher; Dow Jumps 400 Points

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 400 points on Tuesday.

Benzinga

Johnson & Johnson Suspends Sales Forecast For COVID-19 Vaccine, Trims FY22 Profit Outlook

Johnson & Johnson (NYSE:JNJ) has reported Q1 FY22 adjusted earnings of $2.67 per share, up 3.1% Y/Y and ahead of the consensus of $2.61. Net sales increased 5% Y/Y (7.9% on an operational basis) to $23.43 billion, missing the consensus of $23.67 billion. Pharmaceuticals contributed $12.87 billion in sales, +9.3%, due to Darzalex…

Benzinga

Recap: Johnson & Johnson Q1 Earnings

Johnson & Johnson (NYSE:JNJ) reported its Q1 earnings results on Tuesday, April 19, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Benzinga

Earnings Outlook For Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) is set to give its latest quarterly earnings report on Tuesday, 2022-04-19. Here's what investors need to know before the announcement. Analysts estimate that Johnson & Johnson will report an earnings per share (EPS) of $2.61.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Raymond James Thinks Med Tech Investors are Somewhat 'Paralyzed' Ahead Of Q1 Earnings

Raymond James has outlined its expectations for next week when Johnson & Johnson (NYSE:JNJ), Abbott Laboratories (NYSE:ABT), and Intuitive Surgical Inc (NASDAQ:ISRG) will report Q1 FY22 earnings. Analysts believe that the Med Tech investors have become somewhat 'paralyzed' given the macro/factor-driven concerns. On the macro, investor attention seems to be focused less on revenue growth and more…

Benzinga

What 6 Analyst Ratings Have To Say About Johnson & Johnson

Analysts have provided the following ratings for Johnson & Johnson (NYSE:JNJ) within the last quarter:

Benzinga

5 Global Healthcare Stocks to Buy as BofA Warns of a "Recession Shock"

The healthcare industry is well-positioned to ride out a potential recessionary shock, thanks in-part to the inelastic demand for COVID-19 vaccines worldwide. Thus, we think investors could invest in fundamentally sound healthcare stocks Pfizer Inc. (PFE), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), Eli Lilly and Company (LLY), and Merck…

StockNews.com

5 Top Mega-Cap Stocks in the Healthcare Sector to Buy This Month

The healthcare sector is known for its defensive qualities. Therefore, betting on mega-cap healthcare stocks could be one of the best ways to generate stable returns amid the current, extended, market volatility. We think their solid growth attributes and profit margins make the stocks of Novartis (NVS), Danaher (DHR), Eli…

StockNews.com

MindMed Appoints Francois Lilienthal As New CCO

With over twenty years of experience in the biopharmaceutical industry, Francois Lilienthal, MD, has joined Mind Medicine Inc. (NASDAQ:MNMD) as chief commercial officer (CCO). He had been serving as a consultant for the company for the last six months. Lilienthal has a long trajectory with pharmaceutical companies—in 1997, he was…

Benzinga

West Virginia Says J&J, Teva, AbbVie Caused 'Tsunami' Of Opioid Addiction: Reuters

West Virginia's attorney general urged a judge to hold Johnson & Johnson (NYSE: JNJ), Teva Pharmaceuticals Industries Ltd (NYSE: TEVA), and AbbVie Inc's (NYSE:

Benzinga

5 Healthcare Stocks Likely to Withstand a Recession

The healthcare industry has attracted massive investor interest since the onset of the COVID-19 pandemic and could remain in the limelight as COVID cases surge again and necessitate the need for more COVID shots. In addition, the healthcare sector is known to withstand recessions relatively well. So, with several analysts…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

5 Brand-Name Dividend Stocks to Grab Right Now

The stock market is expected to remain under pressure in the near term, given rising concerns over inflation, deepening supply chain disruptions, and the potential for aggressive central bank interest rate increases. For investors seeking ways to dodge market volatility and generate stable returns, we think it could be wise…

StockNews.com

AstraZeneca vs. Johnson & Johnson: Which Drug Manufacturer is a Better Buy?

The COVID-19 pandemic has boosted the revenues of most drug manufacturers. And since healthcare expenditure has been climbing steadily, and because the global population is aging, the demand for medicines is expected to grow. Quality drug manufacturers AstraZeneca (AZN) and Johnson & Johnson (JNJ) should benefit from this trend. But…

Benzinga

Protagonist Therapeutics Earns $25M Milestone Payment From Janssen Biotech

Protagonist Therapeutics (NASDAQ:PTGX) has received a $25 million milestone payment from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE:JNJ). The payment comes after the dosing of the third patient in the Phase 2b FRONTIER 1 clinical trial of PN-235 (JNJ-77242113). FRONTIER 1 is a Phase 2b dose-ranging study to evaluate the…

Benzinga

Expert Ratings For Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) has observed the following analyst ratings within the last quarter:

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What Are Whales Doing With Johnson & Johnson

A whale with a lot of money to spend has taken a noticeably bullish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 21 strange trades.

StockNews.com

5 Stocks to Buy for Stable Income in a Volatile Market

Because concerns over high inflation and increasing sanctions on Russia are expected to fuel stock market volatility in the near term, we think it could be wise to bet on dividend aristocrats Johnson & Johnson (JNJ), Procter & Gamble (PG), PepsiCo (PEP), Abbott (ABT), and Becton Dickinson (BDX) for a…

Benzinga

JNJ Regrets Paying For Controversial Prison Testing With Asbestos: Bloomberg

According to a Bloomberg News report, unsealed court documents show that Johnson & Johnson (NYSE:

Benzinga

This Is What Whales Are Betting On Johnson & Johnson

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 28 strange trades.

Benzinga

Johnson & Johnson's COVID-19 Vaccine Less Effective Against Hospitalization, French Study Shows

According to a large French study, the risk of hospitalization after vaccination with Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine was about five times higher than those who received the Pfizer Inc (NYSE:

Benzinga

This Is What Whales Are Betting On Johnson & Johnson

Someone with a lot of money to spend has taken a bearish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Johnson & Johnson Allowed To Move Ahead With Bankruptcy Strategy On Talc Lawsuits: WSJ

In a federal bankruptcy court in Trenton, New Jersey, Judge Michael Kaplan ruled in favor of Johnson & Johnson's (NYSE: JNJ) controversial bankruptcy filing meant to settle 38,000 claims alleging its talc-based products caused cancer.

1 … 12 13 14 15

People

Patrick Morrisey

79 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.